Welcome to our dedicated page for EVOMMUNE SEC filings (Ticker: EVMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evommune, Inc. files regulatory documents covering its clinical-stage biotechnology business, public-company governance and capital structure. Its 8-K filings furnish operating and financial results, Regulation FD corporate presentations, material-event disclosures and clinical updates for pipeline programs including EVO756 and EVO301.
Evommune’s SEC record also includes registration materials tied to common stock offerings and proxy materials for annual meeting matters. These filings document director elections, auditor ratification, shareholder voting procedures, capital-structure disclosures, material agreements, clinical and regulatory disclosures, and risk factors associated with developing therapies for chronic inflammatory diseases.
Evommune, Inc. director Benjamin F. McGraw III received a grant of stock options covering 15,673 shares of common stock. The options have an exercise price of $19.82 per share and expire on June 1, 2036.
According to the footnote, these options vest at the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, provided he remains in continuous service through that date. Following this grant, he holds options to acquire 15,673 shares directly. This is a routine compensation-related award, not an open-market share purchase or sale.
Evommune, Inc. director Arthur S. Kirsch received a grant of stock options covering 15,673 shares of common stock. The options have an exercise price of $19.82 per share and expire on June 1, 2036. Following this grant, he holds options on 15,673 shares directly.
The award vests at the earlier of the first anniversary of the grant date or Evommune’s next annual meeting of stockholders, as long as Kirsch continues to serve through that vesting date. This is a compensation-related grant, not an open‑market purchase or sale.
Evommune director David E. Cohen reported both stock sales and a new option grant. He sold a total of 6,056 shares of common stock in two open-market transactions at weighted average prices of $20.21 and $21.38, executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 3, 2026.
On the same date, he received a grant of stock options covering 15,673 shares of common stock with an exercise price of $19.82 per share, expiring on June 1, 2036. These options vest at the earlier of the first anniversary of the grant date or Evommune’s next annual meeting of stockholders, as long as he continues to serve through that date.
Evommune, Inc. Chief Scientific Officer Jeegar Pravinkumar Patel reported an exercise-and-sale transaction in company stock. He exercised employee stock options to acquire 13,512 shares of common stock at a price of $3.84 per share, then sold 16,687 shares of common stock at a weighted average price of $22.74 per share in open-market transactions pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2026. Following these transactions, he directly holds 46,403 shares of common stock and 29,330 employee stock options that remain outstanding and exercisable into common stock.
Evommune, Inc. President & CEO Luis C. Pena reported an open-market sale of common stock. On June 1, 2026, he sold 16,787 shares of Evommune common stock at a weighted average price of $22.74 per share in multiple transactions. These trades were made pursuant to a pre-arranged Rule 10b5-1 trading plan. After the sale, Pena directly holds 637,896 shares of Evommune common stock.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting a proposed sale of 9,258 shares of Common StockEVMN on 06/02/2026. The filing lists an aggregate value of $205,249.86 and a reference figure 36,018,372 beside the filing row.
The filing breaks the 9,258 shares into prior allocations, includingPre-IPO purchase of 6,056 shares (06/23/2020) and Restricted Stock Awards of 3,202 shares (05/29/2020). No sales in the past three months are shown in the excerpt.
Evommune, Inc. held its 2026 Annual Meeting of Stockholders and announced director election results and auditor ratification. Luís Peña and Eugene Bauer, M.D. were elected to the Board with reported votes of 21,859,596 and 23,637,920 respectively. The selection of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by a vote of 24,664,299 in favor.
The prospectus supplement updates the S-1 prospectus dated April 24, 2026 and incorporates the Company’s Form 8-K filed June 2, 2026; the supplement refers readers to the Prospectus for risk disclosures. The supplement states the last reported sale price of common stock was $22.17 per share on June 1, 2026.
Evommune, Inc. held its 2026 Annual Meeting of Stockholders on June 2, 2026, with a quorum present. Stockholders elected two directors to serve until the 2029 annual meeting or until their successors are elected and qualified.
Luis Peña was elected with 21,859,596 votes for and 1,949,148 votes withheld, while Eugene Bauer, M.D. received 23,637,920 votes for and 170,824 votes withheld. There were 885,750 broker non-votes for each nominee.
Stockholders also ratified the selection of BDO USA, P.C. as Evommune’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 24,664,299 votes for, 430 votes against, and 29,765 abstentions.
Evommune, Inc. executive Gregory S. Moss reported an exercise-and-sale transaction in company stock. He exercised employee stock options for 14,223 shares of common stock at an exercise price of $1.71 per share and sold 14,223 shares in an open-market transaction at a weighted average price of $22.83 per share. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 26, 2026, indicating they were scheduled in advance. Following the transactions, Moss holds 60,835 shares of Evommune common stock directly and an additional 3,175 shares indirectly through a family trust, and he continues to hold 47,845 employee stock options with a $1.71 exercise price expiring in 2034.
Evommune, Inc. Chief Financial Officer Kyle Carver reported an option exercise and related share sale. On May 28, he exercised options to acquire 15,000 shares of common stock at $2.99 per share and sold 18,175 shares of common stock in open-market transactions at a weighted average price of $22.84 per share.
The filing states these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 26, 2026, indicating they were scheduled in advance. Following the sale, Carver directly holds 59,335 shares of Evommune common stock.